Search

Rocket Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

3.47 4.2

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.27

Макс.

3.49

Ключевые показатели

By Trading Economics

Доход

171M

123M

Прибыль на акцию

-0.15

Сотрудники

202

EBITDA

-1.9M

-47M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+234.43% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

3.3M

397M

Предыдущая цена открытия

-0.73

Предыдущая цена закрытия

3.47

Новостные настроения

By Acuity

27%

73%

97 / 340 Рейтинг в Healthcare

Rocket Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 авг. 2026 г., 22:01 UTC

Rocket Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified. Broader market concerns may be influencing the decline.

13 авг. 2026 г., 19:56 UTC

Rocket Pharmaceuticals Inc shares are lower today, continuing a recent downward trend amid rising U.S. unemployment claims, with no specific company news identified.

12 авг. 2026 г., 19:16 UTC

Rocket Pharmaceuticals Inc shares are lower today, with no specific news driving the decline. Earlier, the stock reached a session high before falling.

11 авг. 2026 г., 20:02 UTC

News

Rocket Pharmaceuticals shares are lower after Wedbush cut its price target to $15, reflecting concerns over mixed second-quarter earnings results.

10 авг. 2026 г., 23:26 UTC

News

Rocket Pharmaceuticals reported Q2 net income of $123.2 million, with EPS of $1.08, significantly exceeding estimates. Shares traded higher in after-market hours.

8 авг. 2026 г., 00:01 UTC

Rocket Pharmaceuticals Inc. shares are higher in after-market trading, advancing modestly since Friday's close and remaining above its 20-day moving average.

7 авг. 2026 г., 23:01 UTC

Rocket Pharmaceuticals Inc. shares have shown little change in after-market trading, remaining within a narrow band since Friday's close.

6 авг. 2026 г., 23:06 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, remaining above its 20-day moving average amid no specific news to explain the movement.

5 авг. 2026 г., 20:02 UTC

News

Rocket Pharmaceuticals is rising Wednesday, driven by a strong Biotechnology sub-sector. The stock remains above its 20-day moving average during the session.

4 авг. 2026 г., 19:26 UTC

News
Event

Rocket Pharmaceuticals shares rise as Wedbush maintains Outperform rating with a $16 price target. The company also reported promising safety results in its Phase 2 trial.

3 авг. 2026 г., 22:01 UTC

Event

Rocket Pharmaceuticals shares are lower in after-market trading despite a positive clinical safety update on its Phase 2 trial for RP-A501.

31 июл. 2026 г., 22:01 UTC

Rocket Pharmaceuticals shares declined in after-hours trading, continuing a downward trend since Friday's close. The stock remains below its 20-day moving average.

30 июл. 2026 г., 21:51 UTC

Rocket Pharmaceuticals is lower in after-market hours, reflecting declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

29 июл. 2026 г., 20:52 UTC

Rocket Pharmaceuticals shares are lower in after-market hours amid a broader market decline driven by rising crude oil prices and geopolitical tensions.

28 июл. 2026 г., 19:22 UTC

Rocket Pharmaceuticals Inc is trading lower today, reflecting broader market trends. The stock remains below its 20-day moving average and near its one-month trading range low.

27 июл. 2026 г., 16:16 UTC

Rocket Pharmaceuticals is trading higher today, recovering from an earlier dip. Broader market volatility follows a notable decline in oil prices amid geopolitical developments.

24 июл. 2026 г., 19:06 UTC

Rocket Pharmaceuticals is trading lower, extending a five-session decline. Broader market pressures and falling crude oil prices are influencing investor sentiment.

22 июл. 2026 г., 20:06 UTC

Rocket Pharmaceuticals shares are lower, marking four consecutive sessions of declines. The stock has closed below its 20-day moving average.

20 июл. 2026 г., 19:46 UTC

News

Rocket Pharmaceuticals shares are higher today amid mixed analyst sentiments, with Wall Street Zen downgrading to "sell" and Chardan Capital maintaining a "buy" rating.

Сравнение c конкурентами

Изменение цены

Rocket Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

234.43% рост

Прогноз на 12 месяцев

Средняя 11.17 USD  234.43%

Максимум 15 USD

Минимум 5 USD

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Rocket Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

8 ratings

5

Покупка

3

Удержание

0

Продажа

Настроения

By Acuity

97 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
help-icon Live chat